ScholarGate
어시스턴트

방법 비교

선택한 방법을 나란히 검토하세요. 서로 다른 행은 강조 표시됩니다.

UCLA 전립선암 지수: 전립선 특이적 삶의 질 기능 평가×EORTC QLQ-LC13: 폐암에서의 삶의 질×
분야종양학종양학
계열Process / pipelineProcess / pipeline
기원 연도19981994
창시자Litwin, M. S., et al.Bergman, B., et al. (EORTC Quality of Life Group)
유형Self-report questionnaireSelf-report questionnaire
원전Litwin, M. S., Hays, R. D., Fink, A., Ganz, P. A., Leake, B., & Brook, R. H. (1998). The UCLA Prostate Cancer Index: development, reliability, and validity of a health-related quality of life measure. Med Care, 36(7), 1002–1012. DOI ↗Bergman, B., Aaronson, N. K., Ahmedzai, S., Kaasa, S., & Sullivan, M. (1994). The EORTC QLQ-LC13: a modular supplement to the EORTC core quality of life questionnaire (QLQ-C30) for use in lung cancer clinical trials. Eur J Cancer, 30A(5), 635–642. DOI ↗
별칭UCLA PCI, PCIQLQ-LC13
관련55
요약The UCLA Prostate Cancer Index (UCLA PCI) is a 20-item, prostate-cancer-specific quality-of-life instrument focused on functional outcomes (urinary, sexual, bowel) rather than general cancer QoL. Developed by Litwin et al. in 1998, it has become the standard functional assessment tool in prostate cancer outcomes research, particularly for treatment comparison studies evaluating surgical vs. radiation outcomes.The EORTC QLQ-LC13 is a 13-item lung-cancer-specific module designed to complement the 30-item EORTC QLQ-C30 core questionnaire. Developed and validated by Bergman et al. in 1994, it measures lung-specific symptoms (dyspnea, cough, hemoptysis, chest pain) and treatment toxicities (sore mouth, dysphagia). It is the standard lung cancer-specific QoL instrument in European and international trials.
ScholarGate데이터셋
  1. v1
  2. 2 출처
  3. PUBLISHED
  1. v1
  2. 2 출처
  3. PUBLISHED

검색으로 이동 슬라이드 다운로드

ScholarGate방법 비교: UCLA Prostate Cancer Index · EORTC QLQ-LC13. 2026-06-20에 다음에서 검색함: https://scholargate.app/ko/compare